Nerida Steel

Cervical screening approach of self-collection, point-of-care HPV testing, and same-day colposcopy among Aboriginal and Torres Strait Islander women in remote Western Australia (the PREVENT Project): an implementation study.

Journal: The Lancet. Public health

Published: March 03, 2025

Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis.

Journal: Papillomavirus research (Amsterdam, Netherlands)

Published: June 08, 2019

RANZCOG Fellows' adherence to guidelines following cytological prediction of cervical adenocarcinoma-in-situ: Cause for concern?

Journal: The Australian & New Zealand journal of obstetrics & gynaecology

Published: May 10, 2018

Risk of persistent or recurrent cervical neoplasia in patients with 'pure' adenocarcinoma-in-situ (AIS) or mixed AIS and high-grade cervical squamous neoplasia (cervical intra-epithelial neoplasia grades 2 and 3 (CIN 2/3)): a population-based study.

Journal: BJOG : an international journal of obstetrics and gynaecology

Published: June 20, 2017

Risk of persistent or recurrent neoplasia in conservatively treated women with cervical adenocarcinoma in situ with negative histological margins.

Journal: Acta obstetricia et gynecologica Scandinavica

Published: November 18, 2016

Risk of persistent and recurrent cervical neoplasia following incidentally detected adenocarcinoma in situ.

Journal: American journal of obstetrics and gynecology

Published: September 21, 2016

Spontaneous regression of CIN2 in women aged 18-24 years: a retrospective study of a state-wide population in Western Australia.

Journal: Acta obstetricia et gynecologica Scandinavica

Published: July 17, 2015

Utilisation of co-testing  (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: - a survey of GPs' awareness and knowledge.

Journal: Australian family physician

Published: February 18, 2015

Comparison of cold knife cone biopsy and loop electrosurgical excision procedure in the management of cervical adenocarcinoma in situ: What is the gold standard?

Journal: Gynecologic oncology

Published: January 14, 2015

Risk of high-grade cervical dysplasia and gynaecological malignancies following the cytologic diagnosis of atypical endocervical cells of undetermined significance: a retrospective study of a state-wide screening population in Western Australia.

Journal: The Australian & New Zealand journal of obstetrics & gynaecology

Published: October 02, 2014

The human papillomavirus Test of Cure: A lesson on compliance with the NHMRC guidelines on screening to prevent cervical cancer.

Journal: The Australian & New Zealand journal of obstetrics & gynaecology

Published: August 21, 2014

The role of general practitioners in the continued success of the National Cervical Screening Program.

Journal: Australian family physician

Published: May 06, 2014

Cervical screening approach of self-collection, point-of-care HPV testing, and same-day colposcopy among Aboriginal and Torres Strait Islander women in remote Western Australia (the PREVENT Project): an implementation study.

Cervical screening approach of self-collection, point-of-care HPV testing, and same-day colposcopy among Aboriginal and Torres Strait Islander women in remote Western Australia (the PREVENT Project): an implementation study.

Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis.

Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis.

RANZCOG Fellows' adherence to guidelines following cytological prediction of cervical adenocarcinoma-in-situ: Cause for concern?

RANZCOG Fellows' adherence to guidelines following cytological prediction of cervical adenocarcinoma-in-situ: Cause for concern?

Risk of persistent or recurrent cervical neoplasia in patients with 'pure' adenocarcinoma-in-situ (AIS) or mixed AIS and high-grade cervical squamous neoplasia (cervical intra-epithelial neoplasia grades 2 and 3 (CIN 2/3)): a population-based study.

Risk of persistent or recurrent cervical neoplasia in patients with 'pure' adenocarcinoma-in-situ (AIS) or mixed AIS and high-grade cervical squamous neoplasia (cervical intra-epithelial neoplasia grades 2 and 3 (CIN 2/3)): a population-based study.

Risk of persistent or recurrent neoplasia in conservatively treated women with cervical adenocarcinoma in situ with negative histological margins.

Risk of persistent or recurrent neoplasia in conservatively treated women with cervical adenocarcinoma in situ with negative histological margins.

Risk of persistent and recurrent cervical neoplasia following incidentally detected adenocarcinoma in situ.

Risk of persistent and recurrent cervical neoplasia following incidentally detected adenocarcinoma in situ.

Spontaneous regression of CIN2 in women aged 18-24 years: a retrospective study of a state-wide population in Western Australia.

Spontaneous regression of CIN2 in women aged 18-24 years: a retrospective study of a state-wide population in Western Australia.

Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: - a survey of GPs' awareness and knowledge.

Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: - a survey of GPs' awareness and knowledge.

Comparison of cold knife cone biopsy and loop electrosurgical excision procedure in the management of cervical adenocarcinoma in situ: What is the gold standard?

Comparison of cold knife cone biopsy and loop electrosurgical excision procedure in the management of cervical adenocarcinoma in situ: What is the gold standard?

Risk of high-grade cervical dysplasia and gynaecological malignancies following the cytologic diagnosis of atypical endocervical cells of undetermined significance: a retrospective study of a state-wide screening population in Western Australia.

Risk of high-grade cervical dysplasia and gynaecological malignancies following the cytologic diagnosis of atypical endocervical cells of undetermined significance: a retrospective study of a state-wide screening population in Western Australia.

The human papillomavirus Test of Cure: A lesson on compliance with the NHMRC guidelines on screening to prevent cervical cancer.

The human papillomavirus Test of Cure: A lesson on compliance with the NHMRC guidelines on screening to prevent cervical cancer.

The role of general practitioners in the continued success of the National Cervical Screening Program.

The role of general practitioners in the continued success of the National Cervical Screening Program.

Utilisation of co-testing  (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: - a survey of GPs' awareness and knowledge.

Utilisation of co-testing  (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: - a survey of GPs' awareness and knowledge.